First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer
Status:
Recruiting
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research is to find if sequential therapy with combined androgen
deprivation or hormonal therapy with luteinizing hormone release hormone (LHRH) analog plus a
new hormonal agent (abiraterone, enzalutamide, or apalutamide) followed by chemohormonal
therapy with docetaxel and LHRH analog would improve the outcome of high risk
metastatic/stage IV prostate cancer.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute